The Relationships Between the High Production of Prostaglandins by Tumors and their Action on Lymphocytes as Suppressive Agents

  • V. Tomasi
  • R. Mastacchi
  • G. Bartolini
  • S. Fadda
  • O. Barnabei
  • R. Gatto
  • F. Barboni
  • A. Trevisani
  • A. Capuzzo
  • M. E. Ferretti
  • M. C. Pareschi
  • G. Martelli
  • R. Danieli
  • S. Rossini


The immune surveillance theory states that cancer cells having foreign antigens on their surfaces, are recognized and destroyed by cells of the immune system before they can grow into a life-threatening tumor. The foreign antigens would be recognized by the immune system triggering the production of cytotoxic T lymphocytes specifically directed against the antigens1.


Natural Killer Cell Human Lymphocyte Human Peripheral Blood Lymphocyte Leukemic Lymphocyte Prostaglandin Action 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. Friedman, S. Specter, I. Kamo, and J. Kateley, Tumor-associated immunosuppressive factors, Ann. N.Y. Acad. Sci. 276: 417 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    B.R. Bloom, Interferons and the immune system, Nature 284: 593 (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    R. Kiessling, E. Klein and H. Wigzell, Natural Killer cells in the mouse. Cytotoxic cells with specificity for mouse maloney leukemia cells: specificity and distribution according to genotype, Europ. J. Immunol. 5: 112 (1975).CrossRefGoogle Scholar
  4. 4.
    R. B. Herberman and H. T. Holden, Natural Killer cells as antitumor effector cells, J. Natl. Cancer Inst. 62: 441 (1979).PubMedGoogle Scholar
  5. 5.
    O. J. Plescia, A. H. Smith and K. D. Grinwich, Subversion of immune system by tumor cells and the role of prostaglandins, Proc. nat. Acad. Sci. USA 72: 1848 (1975).PubMedCrossRefGoogle Scholar
  6. 6.
    S. M. M. Karim and B. Rao, Prostaglandins and tumors, Adv. Prostaglandin Res. 3: 303 (1976).Google Scholar
  7. 7.
    J. S. Goodwin and D. R. Webb, Regulation of the immune response by prostaglandins, Clin. Immunol. Immunopath. 15: 106 (1980).CrossRefGoogle Scholar
  8. 8.
    J. C. Roder and M. Klein, Target effector interaction in the natural killer cell system, J. Immunol. 123: 2785 (1979).PubMedGoogle Scholar
  9. 9.
    M. J. Brunda, R. B. Herberman and H. T. Holden, Inhibition of murine natural killer cell activity by prostaglandins, J. Immunol. 124: 2682 (1980).PubMedGoogle Scholar
  10. 10.
    V. Tomasi, G. Bartolini, M. Orlandi, C. Meringolo and O. Barnabei, Mechanism of action and biological significance of prostaglandin E2 and prostacyclin in the liver, in: “Lipoprotein metabolism and Endocrine regulation”, L. W. Hessel and H. M. J. Krans, eds., Elsevier-North Holland, Amsterdam, 279 (1979).Google Scholar
  11. 11.
    G. Bartolini, C. Meringolo, M. Orlandi and V. Tomasi, Biosynthesis of prostaglandins in parenchymal and non-parenchymal rat liver cells, Biochim. Biophys. Acta 530: 325 (1978).Google Scholar
  12. 12.
    V. Tomasi, C. Meringolo, G. Bartolini and M. Orlandi, Biosynthesis of prostacyclin in rat liver endothelial cells and its control by prostaglandin E2, Nature 273: 670 (1978).PubMedCrossRefGoogle Scholar
  13. 13.
    A. Trevisani, A. Ferretti, A. Capuzzo and V. Tomasi, Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumor growth by non steroidal anti-inflammatory drugs, Br. J. Cancer 41: 341 (1980).PubMedCrossRefGoogle Scholar
  14. 14.
    A. Capuzzo, A. Corallini, E. Fabbri, M. E. Ferretti, M. Pareschi, V. Tomasi and A. Trevisani, Osservazioni preliminari sulla biosintesi in vitro di prostaglandine di tipo E in cellule tumorali e trasformate da virus, Boll. Soc. It. Biol. Sper 57: 2104 (1981).Google Scholar
  15. 15.
    J. W. Smith, A. L. Steiner and C. W. Parker, Human lymphocytic metabolism. Effects of cyclic and non cyclic nucleotides on stimulation by phytohaemagglutinin, J. Clin. Invest. 50: 442 (1971).PubMedCrossRefGoogle Scholar
  16. 16.
    J. D. Stobo, M. S. Kennedy and M. E. Goldyne, Prostaglandin E modulation of the mitogenic response of human T cells, J. Clin. Invest. 64: 1188 (1979).PubMedCrossRefGoogle Scholar
  17. 17.
    A. Novogrodsky, A. L. Rubin and K. H. Stenzel, Selective suppression by adherent cells, prostaglandin and cyclic AMP analogues of blastogenesis induced by different mitogens, J. Immunol. 122: 1 (1979).PubMedGoogle Scholar
  18. 18.
    J. S. Goodwin, S. Bromberg and R. P. Messner, Studies on the cyclic AMP response to prostaglandin in human lymphocytes, Cell. Immunol. 60: 298 (1981).PubMedCrossRefGoogle Scholar
  19. 19.
    D. R. Webb, T. J. Rogers and I. Nowowiesky, Endogenous prostaglandin synthesis and the control of lymphocyte function, Proc. N.Y. Acad. Sci. 332; 262 (1980).CrossRefGoogle Scholar
  20. 20.
    P. Y. K. Wong, J. C. McGiff, F. F. Sun and W. H. Lee, 6-ketoprostaglandin E1 inhibits the aggregation of human platelets, Eur. J. Pharmacol. 60: 245 (1979).PubMedCrossRefGoogle Scholar
  21. 21.
    P. Y. K. Wong, K. U. Malik, D. M. Desiderio, J. C. McGiff and F. F. Sun, Hepatic metabolism of prostacyclin (PGI2) in the rabbit: formation of a potent novel inhibitor of platelet aggregation, Biochem. Biophys. Res. Commun. 93: 486 (1980).PubMedCrossRefGoogle Scholar
  22. 22.
    S. Fadda, R. Mastacchi, G. Romeo, V. Tomasi and O. Barnabei, Regulation of cyclic AMP levels in human lymphocytes and lymphoblasts by prostaglandins, Prost. and Med. 5: 477 (1980).CrossRefGoogle Scholar
  23. 23.
    R. Mastacchi, S. Fadda, V. Tomasi and O. Barnabei, The effect of 6-keto-PGE1 on human lymphocyte cyclic AMP levels, Prost. and Med. 5: 487 (1980).CrossRefGoogle Scholar
  24. 24.
    W. E. Lands and B. Samuelsson, Phospholipids precursors of prostaglandins, Biochim. Biophys. Acta 164: 426 (1968).PubMedGoogle Scholar
  25. 25.
    M. Hamburg, B. Samuelsson, On the metabolism of PGE1 and PGE2 in man, J. Biol. Chem. 246: 6713 (1971).Google Scholar
  26. 26.
    K. V. Honn, R. S. Bockman and L. J. Marnett, Prostaglandins and cancer. A review of tumor initiation through tumor metastasis, Prostaglandins 31: 833 (1981).CrossRefGoogle Scholar
  27. 27.
    P. Polgar, J. Carlos Vera and A. M. Rutenburg, An altered response to cyclic AMP stimulating hormones in intact human leukemic lymphocytes, Proc. Soc. Exp. Biol. Med. 154: 493 (1977).PubMedGoogle Scholar
  28. 28.
    C. R. Kahn, Membrane receptors for hormone and neurotransmitters, J. Cell Biol. 70: 261 (1976).PubMedCrossRefGoogle Scholar
  29. 29.
    C. W. Parker, Control of lymphocyte function, New Engl. J. of Medic. 295 (21): 1180 (1976).Google Scholar
  30. 30.
    J. H. Sanner and K. E. Eakins, Prostaglandin antagonists in: “Prostaglandins: Chemical and biochemical aspects”, S. M. M. Karim, ed., MTP, Lancaster, 139–187 (1976).Google Scholar
  31. 31.
    D. E. Mac Intyre and J. L. Gordon, Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins, Thrombosis Res. 11: 705 (1977).CrossRefGoogle Scholar
  32. 32.
    G. C. Le Breton, D. L. Venton, E. S. Enke and P. V. Halushka, 13 Azoprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor, Proc. Natl. Acad. Sci. USA 76: 4097 (1979).PubMedCrossRefGoogle Scholar
  33. 33.
    D. A. Langs, M. Erman and G. T. De Titta, Conformations of PGF2a and recognition of prostaglandins by their receptors. Science 197: 1003 (1977).PubMedCrossRefGoogle Scholar
  34. 34.
    N. H. Andersen, S. Inamoto, N. Subramanian, D. H. Picker et al., Molecular basis forp prostaglandin potency. III. Tests of the significance of the “Hairpin conformation” in biorecognition phenomena, Prostaglandins 22 (5): 841 (1981).PubMedCrossRefGoogle Scholar
  35. 35.
    D. Brewster, M. Myers, J. Ormerod, A. C. B. Smith, M. E. Spinner and S. Turber, Prostaglandin synthesis design and execution, J. Chem. Soc. Perkin 1: 2796 (1973).CrossRefGoogle Scholar
  36. 36.
    M. Baumgarth and K. Irmscher, Secoandrostansäuren als enantiomere prostaglandin-analoga-I, Tetrahedron 31: 3109 (1975).CrossRefGoogle Scholar
  37. 37.
    G. M. Milne and M. R. Johnson, Levonantradol: a role for central prostanoid mechanisms, J. Clin. Pharmacol. 21 (S): 367S (1981).PubMedGoogle Scholar
  38. 38.
    F. A. Fitzpatrick, G. L. Bundy, R. R. Gorman and T. Honohan, 9,11 Epoxy-Iminoprosta-5,13-Dienoic acid is a thromboxane A2 antagonist in human platelets, Nature 275: 764 (1978).PubMedCrossRefGoogle Scholar
  39. 39.
    V. A. Ferraris and F. R. De Rubertis, Release of prostaglandin by mitogen-and antigen-stimulated leukocytes in culture, J. Clin. Invest. 54: 378 (1974).PubMedCrossRefGoogle Scholar
  40. 40.
    T. Okasaki,S. Masatoshi, C. E. Arbesman and E. Jr. Middleton, Prostaglandin E and mitogenic stimulation of human lymphocytes in serum-free medium, Prostaglandins 15 (3): 423 (1978).CrossRefGoogle Scholar
  41. 41.
    J. S. Goodwin, A. D. Bankhurst, R. P. Messner, Suppression of human T cell mitogenesis by prostaglandin E. E.istence of a prostaglandin producing suppressor cell, J. Exp. Med. 146: 1719 (1977).PubMedCrossRefGoogle Scholar
  42. 42.
    J. S. Goodwin, R. P. Messner, A. D. Bankhurst, G. T. Peake, J. H. Saiki and R. C. Williams Jr, Prostaglandin producing suppressor cells in Hodgkin’s disease, New Eng. J. Med. 297: 263 (1977).CrossRefGoogle Scholar
  43. 43.
    J. S. Goodwin, A. Wiik, M. Lewis, A.D. Bankhurst and C. R. Williams Jr, High affinity binding sites for prostaglandin E on human lymphocytes, Cell Immunol. 43: 150 (1979).PubMedCrossRefGoogle Scholar
  44. 44.
    J. S. Goodwin, P. A. Kaszubowski and C. R. Williams Jr, Cyclic adenosine monophosphate response to prostaglandin E2 on sub-population of human lymphocytes, J. Exp. Med. 150: 1260 (1979).PubMedCrossRefGoogle Scholar
  45. 45.
    K. H. Leung, D. G. Fischer and H. S. Koren, Erythromyeloid tumor cells (K 562) induce PGE synthesis in human peripheral blood monocytes, J. Immunol. 131 (1): 445 (1983).PubMedGoogle Scholar
  46. 46.
    R. M. Schultz, N. A. Pavlidis, W. A. Stylos and M. A. Chirigos, Regulation of macrophage tumoricidal function: a role for prostaglandins of the E series, Science 202: 320 (1978).PubMedCrossRefGoogle Scholar
  47. 47.
    W. F. Stenson and C. W. Parker, PG s, Macrophages and Immunity, J. Immunol. 125: 1 (1980).PubMedGoogle Scholar
  48. 48.
    M. E. Goldyne and J. D. Stobo, PGE2 as a modulator of macrophage-T lymphocyte interactions, J. Invest. Dermatol. 74: 297 (1980).PubMedCrossRefGoogle Scholar
  49. 49.
    D. S. Snyder, D. I. Beller and E. R. Unanne, Prostaglandins modulate macrophage Ia expression, Nature 299: 163 (1982).PubMedCrossRefGoogle Scholar
  50. 50.
    M. E. Snider, R. H. Fertel, and B. S. Zwilling, Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins, Cell Immunol. 74: 234 (1982).PubMedCrossRefGoogle Scholar
  51. 51.
    S. M. Taffet and S. W. Russell, Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by PGE, J. Immunol. 126: 424 (1981).PubMedGoogle Scholar
  52. 52.
    O. J. Plescia, K. Grinwich, J. Sheridan and A. M. Plesia, Subversion of the immune system by tumors as a mechanism of their escape from immune rejection, Prog. Biochem. Pharmacol. 14: 123 (1978).Google Scholar
  53. 53.
    T. Goto, R. B. Herberman, A. Maluish and D. M. Strong, Cyclic AMP as a mediator of Prostaglandin E-induced suppression of human natural killer cell activity, J. Immunol. 130 (3): 1350 (1983).PubMedGoogle Scholar
  54. 54.
    I. Mahnud, N. Fukui and Y. Miura, Arachidonic acid metabolism in normal and regenerating liver and hepatoma, Adv. Enzyme Regul. 18: 27 (1980).CrossRefGoogle Scholar
  55. 55.
    Y. Kanzeki, I. Mahnud, M. Asanagi, N. Fukui and Y. Miura, Thromboxane B2 as possible trigger of liver regeneration, Cell Mol. Biol. 25: 147 (1979).Google Scholar
  56. 56.
    J. S. Goodwin, Prostaglandin synthetase inhibitors as immunoadjuvants in the treatment of cancer, J. Immunopharmacol. 2: 397 (1980).PubMedCrossRefGoogle Scholar
  57. 57.
    M. R. Young and S. Henderson, Enhancement in immunity of tumor bearing mice by immunization against PGE2, Immunol. Commun. 11: 345 (1982).PubMedGoogle Scholar
  58. 58.
    A. Fischer, A. Durandy and C. Griscelli, Role of prostaglandin E2 in the induction of non specific T lymphocyte suppressor activity, J. Immunol. 126: 1452 (1981).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • V. Tomasi
    • 1
  • R. Mastacchi
    • 2
  • G. Bartolini
    • 1
  • S. Fadda
    • 3
  • O. Barnabei
    • 1
  • R. Gatto
  • F. Barboni
    • 4
  • A. Trevisani
  • A. Capuzzo
  • M. E. Ferretti
  • M. C. Pareschi
    • 5
  • G. Martelli
  • R. Danieli
  • S. Rossini
    • 6
  1. 1.Lab. of General PhysiologyUniversity of BolognaItaly
  2. 2.Alfa FarmaceuticiBolognaItaly
  3. 3.Neurological ClinicUniversity of BolognaItaly
  4. 4.Central Laboratory of the Hospital MalpighiBolognaItaly
  5. 5.Institute of General PhysiologyUniversity of FerraraItaly
  6. 6.Istituto dei composti del Carbonio contenenti eteroatomi e loro applicazioniC.N.R.Ozzano Emilia, BolognaItaly

Personalised recommendations